An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

Last updated: February 13, 2026
Sponsor: Zomagen Biosciences Ltd.
Overall Status: Active - Recruiting

Phase

2

Condition

Heart Disease

Cardiac Disease

Chest Pain

Treatment

VTX2735

Clinical Study ID

NCT06836232
VTX2735-202
  • Ages 18-75
  • All Genders

Study Summary

This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP).

Cohort A will include up to 30 participants and will consist of the following:

  • A 30-day Screening Period (to see if a participant qualifies for the study)

  • A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A

  • A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A

  • An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B

  • A 14-day Follow-Up Period

Cohort B will include up to 20 participants and will consist of the following:

  • A 30-day Screening Period (to see if a participant qualifies for the study)

  • A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C

  • An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C

  • A 14-day Follow-Up Period

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants are male or female ≥ 18 years up to ≤ 75 years of age.

  • Capable of giving signed informed consent and able to comply with the protocol

  • Previously had an index (first) episode of pericarditis which met the criteria foran acute pericarditis event

  • Ongoing symptomatic episode of pericarditis, or may have an episode of recurrentpericarditis in the next 4 weeks.

  • CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg/L must be receiving corticosteroid treatment for RPand have evidence of pericardial inflammation)

  • Pericarditis pain score ≥ 4 based on the 11-point NRS.

  • Stable doses of NSAIDs, colchicine, and/or oral corticosteroids (if receiving thesetreatments)

Exclusion

Exclusion Criteria:

  • Current or prior diagnosis of pericarditis that is secondary to specific prohibitedcauses, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis,or systemic autoimmune diseases.

  • History of clinically significant immunosuppressive disorder,autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency.

  • Clinically important history of a medical disorder that would compromise safety ordata quality, per the Investigator's judgment.

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: VTX2735
Phase: 2
Study Start date:
January 28, 2025
Estimated Completion Date:
October 31, 2026

Connect with a study center

  • Local Site #840012

    Tucson, Arizona 85718
    United States

    Site Not Available

  • Local Site #840012

    Tucson 5318313, Arizona 5551752 85718
    United States

    Active - Recruiting

  • Local Site #840014

    Orange, California 92868
    United States

    Site Not Available

  • Local Site #840014

    Orange 5379513, California 5332921 92868
    United States

    Active - Recruiting

  • Local Site #840016

    Saint Augustine, Florida 32086
    United States

    Site Not Available

  • Local Site #840016

    St. Augustine, Florida 32086
    United States

    Site Not Available

  • Local Site #840016

    Saint Augustine 4170894, Florida 4155751 32086
    United States

    Active - Recruiting

  • Local Site #840008

    Chicago, Illinois 60611
    United States

    Site Not Available

  • Local Site #840002

    Park Ridge, Illinois 60068
    United States

    Site Not Available

  • Local Site #840008

    Chicago 4887398, Illinois 4896861 60611
    United States

    Active - Recruiting

  • Local Site #840002

    Park Ridge 4905367, Illinois 4896861 60068
    United States

    Active - Recruiting

  • Local Site #840011

    Owensboro, Kentucky 42303
    United States

    Site Not Available

  • Local Site #840011

    Owensboro 4303436, Kentucky 6254925 42303
    United States

    Site Not Available

  • Local Site #840010

    Boston 4930956, Massachusetts 6254926 02114
    United States

    Active - Recruiting

  • Local Site #840005

    Rochester, Minnesota 55905
    United States

    Site Not Available

  • Local Site #840005

    Rochester 5043473, Minnesota 5037779 55905
    United States

    Active - Recruiting

  • Local Site #840020

    New York 5128581, New York 5128638 10032
    United States

    Active - Recruiting

  • Local Site #840017

    Cleveland 5150529, Ohio 5165418 44195
    United States

    Active - Recruiting

  • Local Site #840001

    Houston, Texas 77034
    United States

    Site Not Available

  • Local Site #840001

    Houston 4699066, Texas 4736286 77034
    United States

    Active - Recruiting

  • Local Site #840019

    Houston 4699066, Texas 4736286 77030
    United States

    Active - Recruiting

  • Local Site #840013

    Salt Lake City, Utah 84132
    United States

    Site Not Available

  • Local Site #840013

    Salt Lake City 5780993, Utah 5549030 84132
    United States

    Active - Recruiting

  • Local Site #840004

    Richmond, Virginia 23219
    United States

    Site Not Available

  • Local Site #840018

    Charlottesville 4752031, Virginia 6254928 22908
    United States

    Active - Recruiting

  • Local Site #840004

    Richmond 4781708, Virginia 6254928 23219
    United States

    Active - Recruiting

  • Local Site #840021

    Seattle 5809844, Washington 5815135 98105
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.